Please login to order a test.
Infliximab Concentration and Anti-Infliximab Antibody
- Anti-TNF-alpha Drug
Provides infliximab drug concentration levels as well as levels of anti-infliximab antibodies.
Failure of infliximab therapy may not always be due to the presence of anti-infliximab antibodies. In addition, the absence of anti-infliximab antibodies does not guarantee positive response to treatment.
Electrochemiluminescence immunoassay (ECLIA)
Infliximab drug level:
• Result ≥0.4 µg/mL indicates detection of infliximab.
• In the presence of anti-infliximab antibodies, the infliximab drug level reflects the antibody-unbound fraction of infliximab concentration in serum.
• Result ≥22 ng/mL indicates detection of anti-infliximab antibodies.
In the absence of anti-infliximab antibodies, the infliximab drug level typically reflects the total infliximab concentration in serum. In the presence of anti-infliximab antibodies, the infliximab drug level typically reflects the antibody-unbound fraction of infliximab concentration in serum. The presence of infliximab drug, even at concentrations well above target treatment levels (>50 μg/mL), does not interfere with the anti-infliximab antibody detection. This assay may be helpful for any patients on infliximab therapy for diseases such as Crohn's disease, inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, or other autoimmune conditions.
1 mL (Note: This volume does not allow for repeat testing.)
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum in a plastic transport tube. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Frozen (preferred) or refrigerated; stable for seven days. Stable at room temperature or refrigerated for seven days. Freeze/thaw cycle: stable x6
To order this test with the serial monitor service, use test 503870 .